Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 entities : Teva pharmaceutical industries ltd save search
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $146.07 0.19% 0.18% 0
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $146.07 0.19% 0.18% 0
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.53 -1.37% -1.37% 0
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.53 -1.37% -1.37% 0
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.53 -1.37% -1.37% 0
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.53 -1.37% -1.37% 0
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $907.32 0.8% 0.74% 460
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 1.67% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.1K
|
Health Technology
| Email alert
Add to watchlist
regn5458 phase 1
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
CZOO | $9.98 100.0% 330K
|
AMST | $3.48 74.0% 21M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.2184 43.4% 36M
|
Consumer Services
ACB | $7.32 16.56% 780K
|
Process Industries
AEYE | $15.42 14.39% 150K
|
Technology Services
BACK | $3.75 13.64% 44K
|
Health Care and Social Assistan...
CGC | $8.835 12.55% 740K
|
Process Industries
BW | News | $1.0002 9.05% 190K
|
Electronic Technology
DXYZ 4 | $30.91 8.49% 73K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.